Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
08 mai 2024 02h30 HE
|
Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
07 mai 2024 16h00 HE
|
Abivax
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 Availability of the preparatory documents PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA (Euronext Paris & Nasdaq:...
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
07 mai 2024 09h19 HE
|
PRISM MarketView
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
07 mai 2024 08h30 HE
|
Inozyme Pharma Inc.
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
07 mai 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
07 mai 2024 04h09 HE
|
AKAMPION
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief...
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
07 mai 2024 03h00 HE
|
Coave Therapeutics
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...
Monthly information on share capital and company voting rights
06 mai 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
06 mai 2024 08h00 HE
|
Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
06 mai 2024 06h25 HE
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...